Infantile Spasms Clinical Trial
Official title:
Sabril Patient Registry
The purpose of this study is to create a patient registry to collect and analyze information on subjects treated with Sabril and the prescribers of Sabril.
This prospective registry is part of the overall Risk Evaluation and Mitigation Strategy
(REMS) required for Sabril by the United States Food and Drug Administration (FDA). All
physicians who prescribe Sabril and all patients who take Sabril will be enrolled in a H.
Lundbeck A/S-sponsored program called "SHARE" (Support, Help and Resources for Epilepsy),
and the data that are collected and entered into the SHARE database will form the basis of
this patient registry.
Prior to any prescription being filled by one of the specialty pharmacies, the prescribing
physician and the patient must be enrolled in SHARE. A call center (SHARE Call Center) will
act as the hub for a network of select specialty pharmacies. Participation in both SHARE and
the patient registry is mandatory.
Information regarding prescriber specialty and location, patient demographic and disease
characteristics will be collected through SHARE and entered into the database. Patients will
be assigned a unique patient identifier upon entry into the registry, and all data related
to that patient will be associated with this identifier.
Early in therapy (within 2-4 weeks for Infantile Spasms patients and 3 months for adult
refractory Complex Partial Seizures patients), a mandatory benefit/risk assessment will
occur. If the benefit of Sabril therapy exceeds the risk of vision loss, the prescribing
physician will complete and submit the appropriate SHARE form and the patient will continue
into the maintenance therapy phase of treatment. The outcome of this benefit/risk assessment
will be entered into the database.
Regular assessments of vision are required during Sabril therapy to contribute information
related to the ongoing benefit/risk assessments. The required assessments will occur at
baseline, every 3 months during therapy, and about 3-6 months after stopping Sabril. The
visual assessment results will be recorded and submitted using the appropriate SHARE forms,
and the data will be entered into the database. A copy of the visual field will be included.
Patients will participate in the registry for as long as they receive Sabril therapy.
Patients who discontinue treatment with Sabril, but are treated with it again at a later
time will be treated as a single patient in the registry.
;
Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02299115 -
Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile Spasms
|
Phase 3 | |
Completed |
NCT02885389 -
Molecular Genetics in Infantile Spasms
|
N/A | |
Completed |
NCT01006811 -
Use of the Modified Atkins Diet in Infantile Spasms
|
Phase 2/Phase 3 | |
Completed |
NCT01828437 -
Addition of Pyridoxine to Prednisolone in Infantile Spasms
|
Phase 3 | |
Recruiting |
NCT01858285 -
Genetics of Epilepsy and Related Disorders
|
||
Completed |
NCT00552045 -
Epilepsy Phenome/Genome Project
|
||
Completed |
NCT02220114 -
Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy
|
N/A | |
Completed |
NCT02954887 -
Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)
|
Phase 3 | |
Completed |
NCT01723787 -
Genetic Studies in Patients and Families With Infantile Spasms
|
||
Completed |
NCT02092883 -
Evaluation of Neuroinflammation in Children With Infantile Spasms
|
Phase 4 | |
Withdrawn |
NCT01413711 -
An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms
|
Phase 4 | |
Completed |
NCT00441896 -
A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms
|
Phase 2 | |
Terminated |
NCT00442104 -
Open-label Extension to Protocol 1042-0500
|
Phase 2 | |
Completed |
NCT01575639 -
Prednisolone in Infantile Spasms- High Dose Versus Usual Dose
|
Phase 3 | |
Withdrawn |
NCT01549288 -
Trial of the Modified Atkins Diet in Infantile Spasms Refractory to Hormonal Therapy
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06315829 -
Artificial Intelligence-based Video Analysis to Detect Infantile Spasms
|
||
Completed |
NCT02953548 -
Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)
|
Phase 3 | |
Completed |
NCT00001325 -
Metabolic Abnormalities in Children With Epilepsy
|
N/A | |
Completed |
NCT00968136 -
Short-term Ketogenic Diet as Compared With Conventional Long-term Trial in Refractory Infantile Spasms: A Randomized, Controlled Study
|
N/A |